Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Trillium Meds vs VyrarX

Trillium Meds
Graded #130

Higher grade

vs+1.1000000000000085
VyrarX
Graded #155

Lower grade

The verdict

Trillium Meds takes it — 69.4/100 to 68.3/100, but only just.

Trillium Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Trillium Meds is a small, owner-operated telehealth platform based in Portland, OR that connects patients with independent licensed providers and FDA-registered compounding pharmacies for compounded… VyrarX is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrillium Meds +10
70
60
Dose & formulationEven
64
64
Clinical oversightEven
84
84
Labs & monitoringTrillium Meds +3
75
72
FulfillmentTrillium Meds +8
79
71
Contract termsVyrarX +35
20
55
Trillium Meds · left barVyrarX · right bar

The numbers

MetricTrillium MedsVyrarX
WeighScore69.4/10068.3/100
GradeCC
Scorecard rank#130#155
Semaglutide$119/mo (3-month plan, compounded)$179/mo (starting dose, compounded)
Tirzepatide$199/mo (3-month plan, compounded)$329/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Trillium Meds

Graded #130 · C

Strengths

  • LegitScript certified with an active seal; serves all 50 states plus Puerto Rico with no geographic restrictions
  • All-inclusive pricing covers medication, provider consultation, and shipping with no hidden fees or add-ons
  • Two pharmacy options (BPI Labs with B6, ProRx) and three plan structures: 1-month, 3-month fixed, or 3-month titrated
  • Small owner-operated; founder personally handles customer support outside business hours for direct, responsive service
  • Klarna and Affirm financing available; pause anytime with no long-term commitment required

Where it loses points

  • No labs, coaching, or clinical monitoring included — telehealth Rx and pharmacy fulfillment only
  • Small single-operator platform may limit capacity and support consistency as patient volume grows
  • Compounded medications are not FDA-approved; newer platform with limited long-term public track record
  • Tirzepatide from $199/mo (3-mo plan) is mid-market; sema from $119/mo competitive but not lowest available
  • No live video consult disclosed; async intake-form-based provider review by external licensed provider network
VyrarX

Graded #155 · C

Strengths

  • LegitScript certified with active seal (ID 51177727)
  • Semaglutide starting at $179/month with free shipping included
  • 1:1 direct provider messaging and personalized titration plan in every plan
  • Nutrition coaching included with the weight-loss program
  • Provider review completed within 24 hours; no insurance required

Where it loses points

  • Tirzepatide at $329/month starting is at the high end of the compounded market
  • Compounding pharmacy not named on any public page
  • No physician names or clinical leadership disclosed publicly
  • Only 47 states covered — the 3 excluded states are not named on the site
  • Labs not included in the weight-loss plan

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard